Ssris in the treatment of obsessive-compulsive disorder

Depression and Anxiety

Volumn 8, Issue SUPPL. 1, 1998, Pages 105-113

  Cartwright, Charles ^a   Hollander, Eric ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Clomipramine; Fluoxetine; Fluvoxamine; Obsessive compulsive disorder; Paroxetine; Sertraline; SSRIs

Indexed keywords

CITALOPRAM; CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; ZIMELDINE;

ARTICLE; CARDIOTOXICITY; CLINICAL TRIAL; DIARRHEA; DROWSINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERACTIVITY; INSOMNIA; LONG TERM CARE; META ANALYSIS; NAUSEA; OBSESSION; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; SEXUAL DYSFUNCTION; TREMOR; VERTIGO; XEROSTOMIA;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DRUG TOLERANCE; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0031788537     PISSN: 10914269     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-6394(1998)8:1+<105::AID-DA16>3.0.CO;2-T     Document Type: Article

References (84)

1. Apter A, Ratzoni G, King RA, Weizman A, Iancu I, Binder M, Riddle MA (1994) Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression. J Am Acad Child Adolesc Psychiatry 33:342-348.
2. Baer L, Jenike MA, Black DW, Treece C, Rosenfeld R, Greist J (1992) Effect of Axis II diagnoses on treatment outcome with clomipramine in 55 patients with obsessive compulsive disorder. Arch Gen Psychiatry 49:862-866.
3. Capstick N (1971) Chlorimipramine in obsessional states. Psychosomatics 12:332-335.
4. Carpenter LL, McDougle CJ, Epperson CN, Price LH (1996) A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder. Drug Safety 15:116-134.
5. CCSG (Clomipramine Collaborative Study Group) (1991) Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 43:730-738.
6. Chouinard G, Goodman W, Greist JH, Jenike M, Rasmussen S, White K, Hackett E, Gaffney M, Bick PA (1990) Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. Psychopharmacol Bull 26:279-284.
7. Como PG, Kurlan R (1991) An open-label trial of fluoxetine for obsessive-compulsive disorders in Gilles de la Tourette's syndrome. Neurology 41:872-874.
8. Cottraux J, Mollard E, Bouvard M, Marks I (1993) Exposure therapy, fluvoxamine, or combination treatment in obsessive-compulsive disorder: One-year followup. Psychiatry Res 49:63-75.
9. DeVeaugh-Geiss J, Moroz G, Biederman J, Cantwell D, Fontaine R, Greist JH, Reichler R, Katz R, Landau P (1992) Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder - a multicenter trial. J Am Acad Child Adolesc Psychiatry 31:45-49.
10. Dominguez RA, Mestre SM (1994) Management of treatment-refractory obsessive compulsive disorder patients. J Clin Psychiatry 55:86-92.
11. Erzegovesi S, Ronchi P, Smeraldi E (1992) 5HT-2 receptor and fluvoxamine effect in obsessive-compulsive disorder. Hum Psychopharmacol 7:287-289.
12. Flament MF, Rapoport JL, Murphy DL, Berg CJ, Lake CR (1987) Biochemical changes during clomipramine treatment of childhood obsessive-compulsive disorder. Arch Gen Psychiatry 44:219-225.
13. Fontaine R, Chouinard G, Iny L (1985) An open clinical trial of zimeldine in the treatment of obsessive compulsive disorder. Curr Ther Res 37:326-332.
14. Freeman CPL, Trimble MR, Deakin JFW, Stokes TM, Ashford JJ (1994) Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: A multicenter, randomized, double-blind, parallel group comparison. J Clin Psychiatry 55:301-305.
15. Geller DA, Biederman J, Reed ED, Spencer T, Wilens TE (1995) Similarities in response to fluoxetine in the treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 34:36-44.
16. Goodman WK, Price LH, Rasmussen SA, Delgado PL, Heninger GR, Charney DS (1989a) Efficacy of fluvoxamine in obsessive-compulsive disorder. Arch Gen Psychiatry 46:36-44.
17. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann R, Hill CL, Heninger GR, Charney DS (1989b) The Yale-Brown Obsessive-Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 46:1006-1011.
18. Goodman WK, Price LH, Delgado PL, Palumbo J, Krystal JH, Nagy LM, Rasmussen SA, Heninger GR, Charney DS (1990) Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 47:577-585.
19. Goodman WK, McDougle CJ, Price LH (1992) Pharmacotherapy of obsessive compulsive disorder. J Clin Psychiatry 53:29-37.
20. Greist JH (1992) Fluvoxamine in OCD: A multicentre parallel design double-blind placebo-controlled trial. Presented at the 18th Collegium Internationale NeuroPsychopharmacologicum Congress, Nice, France, June.
21. Greist JH, Jefferson JW, Kobak KA, Katzelnick DJ, Serlin RC (1995a) Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder: A meta-analysis. Arch Gen Psychiatry 52:53-60.
22. Greist J, Chouinard G, Duboff E, Halaris A, Kim SW, Koran L, Liebowitz M, Lydiard RB, Rasmussen S, White K, Sikes C (1995b) Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 52:289-295.
23. Greist JH, Jefferson JW, Kohak KA, Chouinard G, DuBoff E, Halaris A, Kim SW, Koran L, Liebowitz MR, Lydiard B, McElroy S, Mendels J, Rasmussen S, White K, Flicker C. (1995c) A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 10:57-65.
24. Hollander E (1993) Obsessive-Compulsive Related Disorders. Washington, DC: APA Press.
25. Hollander E, Benzaquen S (1997) The obsessive-compulsive spectrum disorders. Int Rev Psychiatry 9:99-109.
26. Hollander E, DeCaria CM, Nitescu A, Gully R, Suckow RF, Cooper TB, German JM, Klein DF, Liebowitz MR (1992) Serotonergic function in obsessive-compulsive disorder: Behavioral and neuroendocnne responses to oral m-CPP and fenfluramine in patients and healthy volunteers. Arch Gen Psychiatry 49:21-28.
27. Hollander E, Stein DJ, DeCaria M, Saoud JB, Klein DF, Liebowitz MR (1993) A pilot study of biological predictors of treatment outcome in obsessive-compulsive disoder. Biol Psychiatry 33:747-749.
28. Hollander E, Kwon JH, Stein DJ, Broatch J, Rowland CT, Himelein CA (1996) Obsessive-compulsive and spectrum disorders: Overview and quality of life issues. J Clin Psychiatry 57:3-6.
29. Hollander E, Steiner M, Wheadon DE, Bushnell W, Gergel IP (unpublished observation) Long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine.
30. Jenike MA (1986) Theories of etiology. In Jenike MA, Baer L, Minichiello WE (eds): Obsessive Compulsive Disorders: Theory and Management. Littleton, MA: John Wright-PSG, pp 11-21.
31. Jenike MA, Buttolph L, Baer L, Ricciardi J, Holland A (1989) Open trial of fluoxetine in obsessive-compulsive disorder. Am J Psychiatry 146:909-911.
32. Jenike MA, Baer L, Summergrad P, Minichiello WE, Holland A, Seymour R (1990a) Sertraline in obsessive-compulsive disorder: A double-blind comparison with placebo. Am J Psychiatry 147:923-928.
33. Jenike MA, Hyman S, Baer L, Holland A, Minichiello WE, Buttolph L, Summergrad P, Seymour R, Ricciardi J (1990b) A controlled trial of fluvoxamine in obsessive-compulsive disorder: Implications for a serotonergic theory. Am J Psychiatry 147:1209-1215.
34. Jenike MA, Baer L, Greist JH (1990c) Clomipramine versus fluoxetine in obsessive-compulsive disorder: A retrospective comparison of side effects and efficacy. J Clin Psychopharmacol 10:122-124.
35. Kahn RS, Westenberg HGM, Jolles J (1984) Zimeldine treatment of obsessive-compulsive disorder. Acta Psychiatr Scand 69:259-261.
36. Karno M, Golding JM, Sorenson SB, Burnam MA (1988) The epidemiology of obsessive-compulsive disorder in five U.S. communities. Arch Gen Psychiatry 45:1094-1099.
37. Kennett GA, Lightowler S, De Biasi V, Stevens NC, Wood MD, Tulloch IF, Blackburn TP (1994) Effect of chronic administration of selective 5-hydroxytryptamine and noradrenaline uptake inhibitors on a putative index of 5-HT2C/2B receptor function. Neuropharmacology 33:1581-1588.
38. Kim SW, Dysken MW (1990) Open fixed dose trial of fluoxetine in the treatment of obsessive compulsive disorder 19:315-319.
39. Koe BK, Weissman A, Welch WM, Browne RG (1983) Sertraline, 1S,4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthylamine, a new uptake inhibitor with selectivity for serotonin. J Pharmacol Exp Ther 226:686-700.
40. Koponen H, Lepola H, Leinonen E (1995) Citalopram in die treatment of obsessive-compulsive disorder: A report of two cases. Eur Psychiatry 10:209-210.
41. Koran LM, Cain JW, Dominguez RA, Rush AJ, Thiemann S (1996a) Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder? Am J Psychiatry 153:1450-1454.
42. Koran LM, McElroy SL, Davidson JRT, Rasmussen SA, Hollander E, Jenike MA (1996b) Fluvoxamine versus clomipramine for obsessive-compulsive disorder: A double-blind comparison. J Clin Psychopharmacol 16:121-129.
43. Laird LK (1996) Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder. Psychopharmacol Bull 32:569-578.
44. Leonard HL, Swedo SE, Lenane MC, Rettew DC, Cheslow DL, Hamburger SD, Rapoport JL (1991) A double-blind substitution during long-term clomipramine treatment in children and adolescents. Arch Gen Psychiatry 48:922-927.
45. Liebowitz MR, Hollander E, Schneier F, Campeas R, Hatterer J, Papp L, Fairbanks J, Sandberg D, Davies S, Stein M (1989) Fluoxetine treatment of obsessive-compulsive disorder: An open clinical trial. J Clin Psychopharm 9:423-427.
46. Liebowitz MR, Hollander E, Fairbanks J, Campeas R (1990) Fluoxetine for adolescents with obsessive-compulsive disorder (Letter). Am J Psychiatry 147:370-371.
47. Lopez-Ibor JJ Jr, Saiz J, Cottraux J, Note I, Vinas R, Bourgeois M, Hernandez M, Gomez-Perez JC (1996) Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive-compulsive disorder. Eur Neuropsychopharmacol 6:111-118.
48. Mansan ME, Bouchard C, Blier P (1995) Alteration of serotonin release in the guinea pig orbito-frontal cortex by selective serotonin reuptake inhibitors: Relevance to treatment of obsessive-compulsive disorder. Neuropsychopharmacology 13:117-127.
49. Marazziti D, Hollander E, Lensi P, Ravagli S, Cassano GB (1992) Peripheral markers of serotonin and dopamine function in obsessive-compulsive disorder. Psychiatry Res 42:41-51.
50. March JS, Mulle K, Herbei B (1994) Behavioral psychotherapy for children and adolescents with obsessive-compulsive disorder: An open trial of a new protocol driven treatment package. J Am Acad Child Adolesc Psychiatry 33:333-341.
51. March JS, Leonard HL, Swedo SE (1995) Pharmacotherapy of obsessive-compulsive disorder. Child Adolesc Psychiatr Clin North Am 4:217-236.
52. McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH (1994) Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: A double-blind, placebocontrolled study in patients with and without tics. Arch Gen Psychiatry 51:302-308.
53. Montgomery SA, McIntyre A, Osterheider M, Sarteschi P, Zitterl W, Zohar J, Birkett M, Wood AJ, the Lilly European OCD Study Group (1993) A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. Eur Neuropsychopharmacol 3:143-152.
54. Mundo E, Bareggi SR, Piroia R, Bellodi L, Smeraldi E (1997) Long-term pharmacotherapy of obsessive-compulsive disorder: A double-blind controlled study. J Clin Psychopliarmacol 17:4-10.
55. Pato MT, Zohar-Kadouch R, Zohar J, Murphy DL (1988) Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder. Am J Psychiatry 145:1521-1525.
56. Pato MT, Hill JL, Murphy PL (1990) A clomipramine dosage reduction study in the course of long-term treatment of obsessive compulsive disorder patients. Psychopharmacol Bull 26:211-214.
57. Pato MT, Murphy DL, DeVane CL (1991) Sustained plasma concentrations of fluoxetine and/or norfluoxetine four and eight weeks after fluoxetine discontinuation. J Clin Psychopharmcol 11:224-225.
58. Perse TL, Greist JH, Jefferson JW, Rosenfeld R, Dar R (1987) Fluvoxamine treatment of obsessive-compulsive disorder. Am J Psychiatry 144:1543-1548.
59. Piacentini J, Jaffer M, Gitow A, Graae F, Davies SO, Del Bene D, Liebowitz M (1992) Psychopharmacologic treatment of child and adolescent obsessive compulsive disorder. Psychiatr Clin North Am 15:87-107.
60. Piccinelli M, Pini S, Bellantuono C, Wilkinson G (1995) Efficacy of drug treatment in obsessive-compulsive disorder: A meta-analytic review. Br J Psychiatry 166:421-113.
61. Pitman RK (1989) Animal models of compulsive behavior. Biol Psychiatry 26:189-198.
62. Prasad A (1984) A double blind study of imipramine versus zimeldine in treatment of obsessive compulsive neurosis. Pharmacopsychiatry 17:61-62.
63. Price LH, Goodman WK, Charney DS, Rasmussen SA, Heninger GR (1987) Treatment of severe obsessive-compulsive disorder with fluvoxamine. Am J Psychiatry 144:1059-1061.
64. Rapoport JL, Swedo SE, Leonard HL (1992) Childhood obsessive-compulsive disorder. J Clin Psychiatry 53:11-16.
65. Rasmussen SA, Eisen JL, Pato MT (1993) Current issues in the pharmacologie management of obsessive compulsive disorder. J Clin Psychiatry 54:4-9.
66. Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G (1995) Predictors of drug treatment response in obessive-compulsive disorder. J Clin Psychiatry 56:368-373.
67. Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G (1996) Drug treatment of obsessive-compulsive disorder (OCD): Long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs). Psychopharmacol Bull 32:167-173.
68. Renynghe de Voxrie GV (1968) Anafranil (G34586) in obsessive neurosis. Arch Neurol Belg 68:787-792.
69. Riddle MA, Hardin MT, King R, Scahill L, Woolston JL (1990) Fluoxetine treatment of children and adolescents with Tourette's and obsessive compulsive disorders: Preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 29:45-48.
70. Riddle MA, Scahill L, King RA, Hardin MT, Anderson GM, Ort SI, Smith JC, Leckinan JF, Cohen DJ (1992) Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 31:1062-1069.
71. Riddle MA, Landbloom R, Yaryura-Tobias J, Claghorn J, Gaffney G, Greist J, Holland D, McConville B, Pigott T, Pravetz M, Walkup J (1996) Fluvoxamine for OCD in children and adolescents: A controlled trial. Presented at the Annual Meeting of the American Psychiatric Association, New York, May.
72. Robertson MM (1989) The Gilles de la Tourette syndrome: The current status. Br J Psychiatry 154:147-169.
73. Stein DJ, Hollander E (1996) Serotonin specific re-uptake inhibitors in obsessive-compulsive disorder and related disorders. In Feighner JP, Boyer WF (eds): Selective Serotonin Re-uptake In-hibitors, 2nd ed. Chichester, UK: John Wiley & Sons, pp 135-153.
74. Stein DJ, Spadaccini E, Hollander E (1995) Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder. Int Clin Psychopharmacol 10:11-18.
75. Strauss WL, Layton ME, Hayes CE, Dager SR (1997) 19F Magnetic Resonance Spectroscopy investigation in vivo of acute and steady-state brain fluvoxamine levels in obsessive-compulsive disorder. Am J Psychiatry 154:516-522.
76. Thoren P, Asberg M, Bertilsson L, Mellstrom B, Sjoqvist F, Traskman L (1980) Clomipramine treatment of obsessive-compulsive disorder. II. Biochemical aspects. Arch Gen Psychiatry 37:1289-1294.
77. Tollefson GD, Rampey AH, Potvin JH, Jenike MA, Rush AJ, Dominguez RA, Koran LM, Shear MK, Goodman W, Genduso LA (1994a) A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 51:559-567.
78. Tollefson GD, Birkett M, Koran L, Genduso L (1994b) Continuation treatment of OCD: Double-blind and open-label experience with fluoxetine. J Clin Psychiatry 55:69-76.
79. Weissman MM (1993) The epidemiology of obsessive-compulsive disorder. Presented at the First International Conference on Obsessive-Compulsive Disorder, Capri, Italy.
80. Wheadon DE, Bushnell WD, Steiner M (1993) A fixed-dose comparison of 20, 40, or 60mg paroxetine to placebo in the treatment of obsessive-compulsive disorder (Poster). 32nd Annual Meeting of the American College of Neuropsychopharmacology (ACNP), San Juan, Dec.
81. Yaryura-Tobias JA, Neziroglu F, Bergman L (1976) Chlorimiamine, for obsessive-compulsive neurosis: An organic approach. Curr Ther Res 20:541-548.
82. Zohar J, Insel T (1987) Obsessive-compulsive disorder: Psychobiological approaches to diagnosis, treatment, and pathophysiology. Biol Psychiatry 22:667-687.
83. Zohar J, Insel TR, Zohar-Kadouch RC, Hill JL, Murphy DL (1988) Serotonergic responsivity in obsessive compulsive disorder: Effects of chronic clomipramine treatment. Arch Gen Psychiatry 45:167-172.
84. Zohar J, Judge R, OCD Paroxetine Study Investigators (1996) Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. Br J Psychiatry 169:468-474.